Abstract:Abstract Background Despite the advance in neoadjuvant chemothepray/chemoradiotherapy and favourable outcomes of surgical management in supraclavicular lymph node (SCLN) involvement reported in recent studies, the latest AJCC/UICC TMN classification still regards SCLN metastasis as extra-regional i.e Stage IVB (M1) disease. The role of SCLN dissection and surgical management remain controversial. At National University Hospital of the present study, bilateral supraclavicular lymphadenectomy is routinely performed for resectable thoracic ESCC. The aim of this retrospective cohort study is to investigate the long-term outcome of surgical management in pathological SCLN metastasis and its survival benefit comparing to Stage IIB-IVA diseases. Methods Patients with ESCC who underwent esophagectomy and 3-field lymphadenectomy with curative intent between January 2013 and January 2023 at the single centre were included; cases of salvage esophagectomy post-definitive concurrent chemoradiotherapy, palliative resections, and concurrent head and neck cancers were excluded. Neoadjuvant treatments were considered in cases staged clinically as T2 and/or N1 or greater. Pathological status of lymph nodes was recorded according to JES classification. Demographics and prognostic factors were examined using univariant analysis of overall survival (OS). Patients with SCLN metastases and other LN involvements were compared and OS were analysed using Kaplan-Meier method. Results 544 patients were included. 183 had one or more pathological LN metastasis (pN1:126, pN2 46, and PN3: 11) in which 55 patients had SCLN metastasis. Patients with LN metastasis had poorer prognosis than those without (pN0) with a Hazard Ratio (HR) of 2.68 (95% CI, 1.12-3.40, p<0.01); similar pattern was seen in patients with SCLN metastasis (HR 2.28, p<0.01). The 3-year and 5-year OS of patients with SCLN metastasis was 18.5% and 11.6% respectively whereas those of other LN metastasis was 21.4% and 15.8%; the difference between the groups was not statistically significant (p=0.525) (graph 1). Conclusion Lymph node status (pN) is a well-recognised prognostic factor as reaffirmed, however, within the pN positive cohort, long-term survival of patients with SCLN metastasis, considered as stage IVB (M1), was comparable (p<0.05) to those with other LN metastases. This supports the survival benefit of surgical resection with neoadjuvant therapy in SCLN metastases as following nodal disease treatment algorithm; further evaluation including systemic therapy and lymph node sub-group analysis is being conducted. Whilst randomised controlled trials such as Japanese JCOG2013 provides level I evidence, the present study provides complementary real-world experience for SCLN dissection.

[Selective neck dissection and the management of the hypopharyngeal cancer].

[Selective Neck Dissection on the Treatment of Neck Metastases in 63 Patients with Squamous Cell Carcinoma of Hypopharynx].

Efficacy of selective neck dissection: a review of 123 cases of elective and therapeutic treatment of the neck in squamous cell carcinoma of head and neck]

Selective Neck Dissection in the Management of Tongue Squamous Cell Carcinoma with Clinically Negative Nodes

Selective neck dissection for neck residue of nasopharyngeal carcinoma: A prospective study

Selective Versus Comprehensive Neck Dissection in the Treatment of Patients with a Pathologically Node-Positive Neck with or Without Microscopic Extracapsular Spread in Oral Squamous Cell Carcinoma.

Selective Neck Dissection in Surgical Treatment of Papillary Thyroid Cancer

The Management of Metastatic Neck Nodes Following Induction Chemotherapy in N2/3 Classification Hypopharyngeal Carcinoma

Neck Dissection of Level Ib for the Treatment of Cn0 HPV-negative Oropharyngeal Squamous Cell Carcinoma: Should It Be Safely Omitted?

Necessity of level IV dissection in cN0 hypopharyngeal carcinoma

Assessment and Treatment Strategies for Occult Contralateral Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma Patients with Ipsilateral Node-Positive Necks

[Level Choice of the Neck Dissection in Clinical N0 Patients with Supraglottic Cancer].

The role of selective neck dissection in pathological N1 squamous cell carcinomas of the head and neck

Limited neck dissection: is it enough in early oral tongue cancer? Retrospective study

The prognostic value of selective neck dissection in early-stage major salivary gland carcinoma: a population-based analysis

[Outcome of Neck Dissection for 154 Cn0/cn1 Patients with Squamous Cell Carcinoma of Hypopharynx and Prognostic Analysis].

Pattern of regional recurrence after selective neck dissection for clinically positive neck in mucosal squamous carcinoma

Assessment of level IIB lymph nodes in oral cancer - Should we spare or care?

Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis.

Neck Management of Pathological N1 Oral Squamous Cell Carcinoma: a Retrospective Study.

555. SUPRACLAVICULAR NODE INVOLVEMENT, A NODAL OR METASTATIC DISEASE? - A 10-YEAR EXPERIENCE IN ESOPHAGEAL CARCINOMA AT A TERTIARY REFERRAL CENTRE